advanced excimer laser-based vascular and dermatological therapies we are a commercial-stage medical device company leveraging our advanced excimer laser-based platform for use in the treatment of vascular and dermatological diseases. we believe our products enhance patients’ quality of life by restoring blood-flow in arteries and clearing chronic skin conditions. we currently manufacture and market two lines of products: dabra catheter and laser is cleared by the u.s. fda as a tool for the minimally invasive endovascular treatment of vascular blockages resulting from lower extremity vascular disease, which includes peripheral artery disease (pad), which commonly occurs in the legs. pharos excimer laser pharos is designed for use in the treatment of inflammatory skin conditions and is fda cleared as a tool used in the treatment of psoriasis, atopic dermatitis, and leukoderma. our goal is to become the leading medical device company marketing excimer lasers as tools for the treatment of
Company profile
Ticker
VTAK
Exchange
Website
CEO
Jonathan Will McGuire
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Ra Medical Systems, Inc.
SEC CIK
Corporate docs
Subsidiaries
Catheter Precision, LLC ...
VTAK stock data
Latest filings (excl ownership)
8-K
Results of Operations and Financial Condition
2 Apr 24
10-K
2023 FY
Annual report
29 Mar 24
8-K
Unregistered Sales of Equity Securities
25 Jan 24
8-K
CATHETER PRECISION, INC. (VTAK) Reports Unaudited Preliminary Fourth Quarter and Full Year 2023 Results
11 Jan 24
8-K
Departure of Directors or Certain Officers
4 Jan 24
8-K
Departure of Directors or Certain Officers
29 Dec 23
EFFECT
Notice of effectiveness
29 Dec 23
EFFECT
Notice of effectiveness
29 Dec 23
POS AM
Prospectus update (post-effective amendment)
22 Dec 23
POS AM
Prospectus update (post-effective amendment)
22 Dec 23
Transcripts
VTAK
Earnings call transcript
2022 Q1
17 May 22
VTAK
Earnings call transcript
2021 Q4
24 Mar 22
VTAK
Earnings call transcript
2021 Q3
16 Nov 21
VTAK
Earnings call transcript
2021 Q2
17 Aug 21
VTAK
Earnings call transcript
2021 Q1
11 May 21
VTAK
Earnings call transcript
2021 Q1
17 Mar 21
VTAK
Earnings call transcript
2020 Q4
13 Nov 20
VTAK
Earnings call transcript
2020 Q2
11 Aug 20
VTAK
Earnings call transcript
2020 Q1
14 May 20
VTAK
Earnings call transcript
2019 Q4
10 Mar 20
Latest ownership filings
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
4
DAVID A JENKINS
24 Jan 24
4
DAVID A JENKINS
22 Jan 24
4
DAVID A JENKINS
18 Jan 24
SC 13D/A
JENKINS DAVID A
16 Jan 24
4
John P. Francis,
10 Jan 24
3
John P. Francis,
10 Jan 24
4
Margrit Thomassen
10 Jan 24
4
MARTIN J COLOMBATTO
10 Jan 24
4
James Joseph Caruso
10 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 5.58 mm | 5.58 mm | 5.58 mm | 5.58 mm | 5.58 mm | 5.58 mm |
Cash burn (monthly) | 610.33 k | 673.17 k | 910.00 k | 6.98 mm | 610.00 k | 1.81 mm |
Cash used (since last report) | 4.14 mm | 4.57 mm | 6.18 mm | 47.39 mm | 4.14 mm | 12.31 mm |
Cash remaining | 1.43 mm | 1.01 mm | -601.11 k | -41.81 mm | 1.44 mm | -6.73 mm |
Runway (months of cash) | 2.3 | 1.5 | -0.7 | -6.0 | 2.4 | -3.7 |
Institutional ownership, Q2 2023
21.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 15 |
Opened positions | 5 |
Closed positions | 3 |
Increased positions | 0 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 340.37 mm |
Total shares | 1.54 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
David A Jenkins | 709.70 k | $1.20 mm |
Randall Rollins Voting Trust U/A dated August 25, 1994 R. | 261.55 k | $442.00 k |
Armistice Capital | 208.94 k | $192.23 mm |
Intracoastal Capital | 152.61 k | $1.13 mm |
Baird Financial | 100.58 k | $92.54 mm |
Renaissance Technologies | 36.10 k | $33.00 k |
BLK Blackrock | 18.44 k | $16.96 mm |
Citadel Advisors | 17.49 k | $16.09 mm |
Geode Capital Management | 13.17 k | $12.11 mm |
VIRT Virtu Financial | 12.69 k | $12.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
23 Jan 24 | David A Jenkins | Common Stock | Buy | Acquire P | No | No | 0.5976 | 9,528 | 5.69 k | 329,856 |
22 Jan 24 | David A Jenkins | Common Stock | Buy | Acquire P | No | No | 0.4295 | 9,528 | 4.09 k | 320,328 |
19 Jan 24 | David A Jenkins | Common Stock | Buy | Acquire P | No | No | 0 | 8,470 | 0.00 | 310,800 |
18 Jan 24 | David A Jenkins | Common Stock | Buy | Acquire P | No | No | 0 | 8,470 | 0.00 | 302,330 |
16 Jan 24 | David A Jenkins | Common Stock | Buy | Acquire P | No | No | 0.3912 | 8,470 | 3.31 k | 293,860 |
16 Jan 24 | David A Jenkins | Common Stock | Buy | Acquire P | No | No | 0.3862 | 7,793 | 3.01 k | 285,390 |
8 Jan 24 | John P. Francis, | Options Common Stock | Grant | Acquire A | No | No | 0 | 25,000 | 0.00 | 25,000 |
8 Jan 24 | Margrit Thomassen | Options Common Stock | Grant | Acquire A | No | No | 0 | 25,000 | 0.00 | 25,000 |
Press releases
Exploring Emerging Companies with Key Developments Garnering Attention: INBS, INVO, VTAK, RCAT, GCTK
19 Apr 24
Ladenburg Thalmann, Esteemed Wall Street Long-Standing Stalwart Since 1876, Advocates 'Buy' for Intelligent Bio, Precision Bio, and More: VTAK, INBS, LASE, MYMD, RVSN
9 Apr 24
Catheter Precision, Inc. (NYSE-American:VTAK) Expands Sales Team; Expects Corresponding Rise in Revenue Over the Near Term; Anticipates Breakeven by End of Year
4 Apr 24
Reddit Inc. (NYSE: RDDT) Surges, Uncovering Undervalued Opportunities: DYAI, INBS, MESO, VTAK
28 Mar 24
Trump Media (NASDAQ: DJT) Soars 24%: Opens at $71.93, Ignites Market Buzz Among DYAI, INBS, VTAK
28 Mar 24